Cisplatin

Cisplatin
Product Description

Johnson matthey pharma services offers a wide range of products which includes cisplatin. Features: it is anti-cancer. Contact us for more information.

Johnson Matthey

  • US
  • 2015
    On CPHI since
  • 1
    Certificates
  • 5000+
    Employees
Company types
Contract Service
Primary activities
Agrochemical
Chemical Development
Contract Manufacturer
Contract Research Organisation
Custom Manufacturing/Custom Synthesis
Specifications
  • CAS Registry Number
    15663-27-1
  • Selling Points
    Product Features; Quality Service
  • Supplied from
    United States

Johnson Matthey

  • US
  • 2015
    On CPHI since
  • 1
    Certificates
  • 5000+
    Employees
Company types
Contract Service
Primary activities
Agrochemical
Chemical Development
Contract Manufacturer
Contract Research Organisation
Custom Manufacturing/Custom Synthesis

More Products from Johnson Matthey (29)

  • Alfentanil HCl

    Product Alfentanil HCl

    CEPUSDMF
    RoW DMF
  • Apomorphine hydrochloride

    Product Apomorphine hydrochloride

    Johnson matthey pharma services offers a wide range of products which includes apomorphine hydrochloride. Features: it is used in treatment of parkinson’s disease. Contact us for more information.
  • Atropine Sulfate

    Product Atropine Sulfate

    Our Controlled Substance and API Portfolio is supported by a global network of GMP facilities: West Deptford, NJ; Devens, MA; North Andover, MA; Edinburgh, UK and Annan, UK.
  • Auranofin

    Product Auranofin

    Johnson matthey pharma services offers a wide range of products which includes auranofin. Features: it is anti-rheumatic. Contact us for more information.
  • Carboplatin

    Product Carboplatin

    Johnson matthey pharma services offers a wide range of products which includes carboplatin. Features: it is anti-cancer. It is used to treat ovarian, head and neck cancer. Contact us for more information.
  • Carmustine

    Product Carmustine

    Johnson matthey pharma services offers a wide range of products which includes carmustine. Features: it is anti-cancer. Contact us for more information.
  • Decitabine

    Product Decitabine

    Johnson matthey pharma services offers a wide range of products which includes decitabine. Features: it is used in treatment of myelodysplastic syndromes (mds). Contact us for more information.
  • Dofetilide

    Product Dofetilide

    Our Controlled Substance and API Portfolio is supported by a global network of GMP facilities: West Deptford, NJ; Devens, MA; North Andover, MA; Edinburgh, UK and Annan, UK.
  • Edrophonium chloride

    Product Edrophonium chloride

    Johnson matthey pharma services offers a wide range of products which includes edrophonium chloride. Features: it used to reverse muscle relaxant effects during or after surgery. Contact us for more information.
  • Naloxone hydrochloride

    Product Naloxone hydrochloride

    Johnson matthey pharma services offers a wide range of products which includes naloxone hydrochloride. Features: it is used for opioid overdose; opioid dependence; analgesia. Contact us for more information.
  • Amphetamine Aspartate

    Product Amphetamine Aspartate

    Our Controlled Substance and API Portfolio is supported by a global network of GMP facilities: West Deptford, NJ; Devens, MA; North Andover, MA; Edinburgh, UK and Annan, UK.
  • Enzyme kits

    Product Enzyme kits

    We offer biocatalysts and enzymes for the development of substances used in pharmaceuticals, agrochemicals and other fine chemicals from initial screening to commercial scale supply. Our range of biocatalysts complement the chiral capabilities of our chemo-catalyst technology offering. Using our biocatal...

Johnson Matthey resources (10)

  • News JM to manufacture regulatory starting materials for Sarepta Therapeutics

    Johnson Matthey (JM), a global leader in science that enables a cleaner and healthier world, has entered into a five-year supply agreement with Sarepta Therapeutics, Inc. to continue supplying regulatory starting materials to support Sarepta’s phosphorodiamidate morpholino oligomer (PMO) and peptide phosphorodiamidate morpholino oligomer (PPMO) programmes used for the treatment of Duchenne Muscular Dystrophy.
  • Brochure JM-Pharmaceutical Products and Services Brochure

    JM provides complex chemistry solutions to the pharma market to create a healthier world. We have vast industry experience, access to specialist technologies and capabilities, and a 200-year heritage.
  • News Johnson Matthey partners with Immunomedics to develop lifesaving cancer treatment

    Johnson Matthey (LSE: JMAT), a global leader in science that enables a cleaner and healthier world, announced a strategic manufacturing partnership for the large-scale production of the drug-linker used in Immunomedics’ lead antibody-drug conjugate. 
  • Brochure JM-Solid State Services Flyer

    Our expertise in solid state pharmaceutical studies helps to enhance your drug discovery and development by enabling better products and a faster route to market.
  • Brochure JM-Catalysts Product Guide

    Johnson Matthey provides a portfolio of advanced heterogeneous catalysts, homogeneous chemocatalysts and biocatalysts. Our expert technical teams will deliver the solutions you need for more cost effective, efficient and sustainable chemistry.
  • Brochure Solid form science flyer

    Johnson Matthey has leading capabilities in developing optimal polymorphs, salt forms, crystal morphology and controlled particles through our PHARMORPHIX®️ solid form sciences. We offer one of the broadest and most reliable services to ensure effective identification, development and manufacture of your drug candidates and commercial products.
  • Brochure Catalyst product guide

    Johnson Matthey provides a portfolio of advanced heterogeneous catalysts, homogeneous chemocatalysts and biocatalysts for the pharmaceutical market.
  • Brochure API and Controlled Substance Product Guide

    Our Controlled Substance and API Portfolio is supported by a global network of GMP facilities: West Deptford, NJ; Devens, MA; North Andover, MA; Edinburgh, UK and Annan, UK
  • Whitepaper White paper - Crystallisation process development, Providing a first-choice opportunity

    In the manufacture of active pharmaceutical ingredients (APIs), crystallisation is a key unit operation. The importance of designing the solid state and particle form of a given API is well-appreciated in the industry as it can impact the downstream processability of the isolated material and can be used to maximise the efficacy of the final drug. Crystallisation provides the first-choice opportunity to achieve this designed particle, however, historically time and cost pressures have inhibited developing the understanding required for robust and reliable processes at an early stage. Consequently, issues such as oiling out, solvent and impurity entrapment, multimodal particle size distributions and previously unseen polymorph transitions have been all too common to first be seen upon process scale-up, often requiring significant quantities of additional time and investment to circumvent.
  • Video Johnson Matthey: Inspiring Science, Enhancing Life video

    Our vision is for a world that's cleaner and healthier, today and for future generations.